MedPath

Prospective Huntington At Risk Observational Study

Conditions
Huntington Disease
Registration Number
NCT00052143
Lead Sponsor
Huntington Study Group
Brief Summary

The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.

Detailed Description

Huntington's disease (HD) is a genetic disease characterized by changes in movement and behavior. To date, little research has been done on individuals who are at risk for developing the disease. PHAROS is an observational study designed to monitor people who are at risk for developing HD, and to survey their attitudes and beliefs about their "at-risk" status. Investigators hope this study will help answer some important questions about HD, such as: 1.) What are the earliest signs of HD and when do they start? 2.) How accurate are the measures that physicians use in detecting the onset of HD? 3.) What factors influence the age at which a person carrying the HD gene develops the illness? and 4.) In a group of people at risk for HD, how many will develop signs of the illness over a minimum three-year period of observation?

Participants in the study will be evaluated every 9 months (for 5 years) using the Unified Huntington's Disease Rating Scale (UHDRS)--a clinical tool which looks at movement, psychological and behavioral function. The participants will also be asked to complete surveys about their mood, life events, and attitudes or beliefs about being at risk for HD. A blood sample, taken at the beginning of the study, will be confidentially tested to determine if the participant has the abnormal gene for HD. Neither the participant nor any of the PHAROS physicians or coordinators will learn the results of individual gene tests.

The scientists hope that this study will provide essential information for future trials of experimental drugs for HD.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1001
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (42)

University of Alabama

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

Mayo Clinic Arizona

πŸ‡ΊπŸ‡Έ

Phoenix, Arizona, United States

University of California at San Diego

πŸ‡ΊπŸ‡Έ

La Jolla, California, United States

UCLA School of Medicine

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

University of California, Davis

πŸ‡ΊπŸ‡Έ

Sacramento, California, United States

Colorado Neurological Institute

πŸ‡ΊπŸ‡Έ

Englewood, Colorado, United States

University of Connecticut

πŸ‡ΊπŸ‡Έ

Hartford, Connecticut, United States

Institute for Neurodegenerative Disorders

πŸ‡ΊπŸ‡Έ

New Haven, Connecticut, United States

University of Miami School of Medicine

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

University of South Florida

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Scroll for more (32 remaining)
University of Alabama
πŸ‡ΊπŸ‡ΈBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.